Genworth Financial, Inc. (GNW) Stock Research Report

A deep discount to Enact’s value funds a CareScout “silver tsunami” option—if Genworth can keep legacy LTC tail risk contained.

Executive Summary

Genworth has transitioned from a distressed legacy insurer into a bifurcated story: a strong U.S. mortgage insurance franchise housed in Enact (Genworth owns ~81%) paired with an emerging, capital-light CareScout platform targeting the aging-care crisis, while a Closed Block of legacy LTC/life/annuity policies remains the principal source of volatility. Enact is the current economic engine, delivering substantial adjusted operating income and upstreaming meaningful capital to the holding company. CareScout is positioned as a scalable ecosystem for finding and funding care, showing accelerating adoption and expanding its provider network and product set. The legacy Closed Block is being de-risked through MYRAP rate actions and benefit adjustments, but remains exposed to actuarial tail risk. Despite improved capital management (large buybacks and deleveraging), the market continues to price GNW as if legacy liabilities overwhelm other assets—often implying a valuation below the fair value of the Enact stake alone.

Full Research Report

Genworth Financial Inc (GNW) Investment Analysis:

1. Executive Summary:

Genworth Financial Inc (GNW) stands at a critical juncture in its corporate evolution, having successfully transitioned from a distressed legacy insurer into a bifurcated enterprise defined by a robust, cash-generative mortgage insurance business and a burgeoning, capital-light platform focused on the domestic aging-care crisis.[1, 2] The company, headquartered in Richmond, Virginia, operates as a holding company with a diverse array of subsidiaries that generate revenue through three primary mechanisms: mortgage insurance premiums, legacy insurance policy fees, and an emerging suite of fee-based services for long-term care navigation.[3]

The primary engine of Genworth’s current financial viability is its approximately 81% majority ownership of Enact Holdings, Inc. (ACT), a leading provider of private mortgage insurance (PMI) in the United States.[4, 5] Enact generates revenue by providing credit protection to mortgage lenders—including national banks, non-bank mortgage lenders, and credit unions—on low-down-payment loans.[6, 7] By covering a portion of the unpaid principal in the event of a borrower default, Enact enables these lenders to sell their mortgages into the secondary market, primarily to Government-Sponsored Enterprises (GSEs) such as Fannie Mae and Freddie Mac.[6, 7] In the fiscal year ended December 31, 2025, Enact remained the cornerstone of the consolidated entity’s profitability, contributing $558 million in adjusted operating income and providing $407 million in capital returns to the Genworth holding company.[8, 9]

Complementing the mortgage insurance business is Genworth’s strategic pivot toward the senior care market via its CareScout subsidiary.[3, 5] CareScout is designed to be a data-driven, scalable services platform that addresses the "Silver Tsunami"—the demographic shift where 71 million Americans will be aged 65 or older by 2029.[2, 9] This segment generates revenue through a "Quality Network" of home-care and senior-living providers, offering fee-based care plans, provider matching services, and standalone long-term care insurance products.[9, 10] In 2025, CareScout facilitated over 3,255 matches between care seekers and providers, representing a significant acceleration in platform adoption.[9, 11]

The third component of Genworth’s operations is the "Closed Block," which consists of legacy long-term care (LTC), life insurance, and annuity products that are no longer actively sold through the main legacy subsidiary, Genworth Life Insurance Company (GLIC).[12, 13] This block is managed as a self-sustaining system, where revenue is derived from existing premiums and investment income from a $59 billion asset portfolio, while expenses are driven by policyholder claims and benefits.[1, 3, 10] Management’s strategy for this segment is focused exclusively on de-risking through a Multi-Year Rate Action Plan (MYRAP), which has achieved an estimated $34.5 billion in net present value (NPV) from premium increases and benefit reductions since 2012.[3, 9]

For the full year 2025, Genworth reported consolidated annual revenue of $7.3 billion and net income of $223 million, or $0.54 per diluted share.[3, 8] While GAAP net income reflects the volatility of legacy claims, the company’s capital management has been disciplined, with $790 million in share repurchases executed since 2022 and a reduction of the share count by approximately 24%.[1, 11] The resulting investment profile is that of a complex financial entity where the market currently discounts the legacy liabilities heavily, often resulting in a valuation that is lower than the fair market value of the company’s stake in Enact alone.[5]

2. Business Drivers & Strategic Overview:

The strategic trajectory of Genworth Financial is propelled by three distinct business drivers: the resilience of the U.S. mortgage market, the demographic inevitability of the aging population, and the internal operational success of the legacy block de-risking strategy.[2, 9, 14]

Mortgage Insurance and the Enact Engine

Enact serves as the financial bedrock of the enterprise, driven by persistent demand for low-down-payment home loans.[6, 7] The segment’s revenue is a function of primary insurance in-force (IIF), which grew to $273.1 billion by year-end 2025.[8, 12] The primary driver of profitability in this segment is the "persistence" of existing policies; in a high-interest-rate environment, borrowers are less likely to refinance, keeping their mortgage insurance policies active for longer durations and generating more cumulative premium revenue.[7, 15]

Enact’s competitive advantage lies in its high-quality underwriting and robust capital position.[6, 16] The insured portfolio boasts a weighted average FICO score of 746 and is protected by extensive credit risk transfer (CRT) programs, including excess-of-loss reinsurance and mortgage insurance-linked notes.[6] These mechanisms allow Enact to maintain a PMIERs (Private Mortgage Insurer Eligibility Requirements) sufficiency ratio of 162%, representing $1,919 million in capital above requirements.[1, 12] This capital strength supports consistent dividend payouts and share repurchases, which are then used by Genworth to fund its own strategic growth and debt retirement.[1, 5]

The CareScout Expansion and Fee-Based Pivot

CareScout represents the company’s long-term growth initiative, pivoting Genworth from a capital-intensive insurance model to a capital-light services model.[2, 5] The strategic vision for CareScout is to become an "integrated ecosystem" for finding and funding long-term care.[2, 17]

Key growth initiatives for CareScout include:
* The CareScout Quality Network (CQN): This network has expanded to 789 home-care providers across 1,058 locations, covering 97% of the U.S. population aged 65 and older.[5, 9] By credentialing these providers and negotiating discounts, CareScout creates a unique value proposition for both individual families and third-party payers.[2, 5]
* Care Assurance Insurance: Launched in October 2025, this modern LTC product is active in 40 states and features conservative pricing aligned with current actuarial realities.[9, 10]
* Strategic Acquisitions: The acquisition of Seniorly in late 2025 allows CareScout to move beyond home-care provider matching into the senior living and assisted living markets, significantly increasing the platform's Total Addressable Market (TAM).[1, 9]
* Revenue Scaling: Management has established a revenue target of at least $25 million for CareScout Services in 2026, with longer-term goals of achieving $50–100 million in Annual Recurring Revenue (ARR) within 3–5 years.[2, 5]

The Closed Block and MYRAP Implementation

The "Closed Block" is driven by the necessity of stabilizing the legacy LTC and life insurance liabilities.[1, 12] The primary driver here is the Multi-Year Rate Action Plan (MYRAP), which involves obtaining regulatory approvals for premium increases and offering policyholders the option to reduce their benefits in exchange for lower premium costs.[1, 9]

In 2025, Genworth achieved $209 million in gross incremental premium approvals, which contributes to the overall $34.5 billion in economic benefit realized since 2012.[3, 9] A critical competitive advantage in this segment is Genworth's extensive data on long-term care claims, which spans over 50 years and $35 billion in paid benefits.[9, 10] This data informs the company’s actuarial assumptions and gives it superior insight into how to manage the "tail risk" of its oldest policyholders.[2, 10]

3. Financial Performance & Valuation:

2025 Financial Summary

The fiscal year 2025 was a period of operational stabilization for Genworth, despite the challenges inherent in its legacy block.[8, 12] The company’s consolidated financials are summarized in the following table:

Consolidated Metric (FY 2025) Amount (USD Millions) Per Diluted Share
Total Revenue $7,300 --
Net Income Available to Stockholders $223 $0.54
Adjusted Operating Income $144 $0.35
Enact Adjusted Operating Income $558 --
Closed Block Adjusted Operating Loss ($317) --
Holding Company Cash and Liquid Assets $234 --
Consolidated RBC Ratio (Legacy Units) 300% --

[3, 8, 11]

The performance of Enact remained the primary driver of income, while the Closed Block segment experienced an adjusted operating loss of $317 million for the year.[8, 11] This loss was largely attributed to a $159 million loss in the fourth quarter in the LTC line, driven by higher-than-expected claims and unfavorable assumption updates regarding mortality and benefit utilization.[8, 12] However, the Enact segment's strong performance—with a loss ratio of only 7% in Q4 2025—largely offset these pressures at the consolidated level.[8, 12]

Valuation Metrics

As of March 20, 2026, Genworth Financial’s common stock (GNW) was priced at $7.99 per share.[3, 18] The market capitalization of approximately $3.1 billion suggests a profound disconnect from the company's book value and the market value of its subsidiary holdings.[1, 18]

Valuation Metric (as of March 2026) Value
Current Share Price $7.99
Market Capitalization ~$3.1 Billion
Book Value (Total Equity) $9.232 Billion
Book Value per Share (GAAP) ~$23.56
Book Value per Share (Excluding AOCI) ~$25.86
Price-to-Book (P/B) Ratio ~0.34x
Price-to-Earnings (P/E) Ratio (TTM) 14.83x

[8, 18, 19]

A "sum-of-the-parts" analysis reveals that Genworth's 81% stake in Enact Holdings is currently worth approximately $4.8 billion (based on Enact’s market cap of ~$5.9 billion).[4, 20] This means that the equity market is valuing Genworth’s other assets—including the $234 million in cash, the CareScout platform, and the multi-billion dollar investment portfolio—at a negative $1.7 billion.[5, 11] This steep discount is a direct reflection of the market’s caution regarding the potential for future "black swan" claim events in the legacy long-term care block.[5]

Investment Portfolio and Capital Structure

The company manages a vast investment portfolio totaling $59 billion as of December 31, 2025.[3, 19] This portfolio is primarily composed of investment-grade fixed maturity securities (75% of total investments), with 97% of those rated BBB or higher.[15, 19] Genworth has been active in retiring debt, reducing its total long-term borrowings to approximately $1.5 billion, while the parent holding company has reduced its specific debt to $783 million.[5, 19] This deleveraging provides the company with significant financial flexibility to fund its share repurchase program and its CareScout expansion.[1, 5]

4. Risk Assessment & Macroeconomic Considerations:

Genworth Financial is exposed to a unique intersection of risks involving the U.S. housing market, the healthcare labor market, and complex actuarial volatility.

Macroeconomic Drivers and Housing Market Sensitivity

Enact’s performance is intrinsically linked to the U.S. housing economy. While high interest rates have benefitted premium persistence, they also pose a risk by reducing new insurance written (NIW) due to deteriorating home affordability.[7, 14] Fitch Ratings notes that the mortgage insurance sector is on "solid footing" due to strict capital requirements, but identifies a potential economic downturn as the principal risk to profitability in 2026 and 2027.[16]

The credit quality of Enact’s existing book is a major mitigating factor; 98% of the loans underwritten are 30-year fixed-rate mortgages, which are less sensitive to immediate interest rate shocks.[14] However, S&P Global expects mortgage delinquencies to rise slightly in 2026 as unemployment potentially "nudges upward," which could elevate loss ratios from their current historic lows.[16, 21]

Actuarial and Claim Volatility in the Closed Block

The most significant risk to the Genworth thesis is the "tail risk" of the legacy LTC block.[5, 10] Because the peak claim years for this block are still over a decade away, the company's current reserves are based on long-term projections of mortality, morbidity, and interest rates.[5, 10] In the fourth quarter of 2025, unfavorable experience—including higher claims and lower policy terminations—resulted in a $124 million pre-tax loss, illustrating how small deviations from actuarial assumptions can impact quarterly results.[8, 12]

Management has attempted to mitigate this by managing the block as a "closed system" and pledging not to contribute additional parent-company capital to the legacy entities.[5, 10] While this provides some protection to the holding company, a catastrophic reserve failure could still lead to regulatory intervention that might disrupt the company’s ability to extract capital from other subsidiaries.[2, 10]

Inflationary Pressures on Care Costs

The CareScout platform and the legacy LTC block are both sensitive to the cost of care services.[22, 23] The 2025 Cost of Care Survey revealed that while growth has slowed, the median hourly rate for a non-medical caregiver remains historically high at $35 per hour, or roughly $80,000 annually for 44 hours of care per week.[22] Continued labor shortages in the nursing and caregiving sectors could drive these costs higher, putting pressure on the "burn rate" of policyholder benefits and making standalone insurance products more expensive to underwrite.[22, 24]

Legal and Strategic Contingencies

Genworth is currently pursuing a potential $750 million recovery from AXA litigation.[11] A favorable court decision—expected in late 2026 or early 2027—would serve as a massive liquidity catalyst for the company.[11] Conversely, a negative outcome would represent a missed opportunity for further debt reduction or share repurchases, although it is not currently factored into management’s capital allocation plans.[5]

5. 5-Year Scenario Analysis:

The following five-year projections for Genworth Financial assume a continued strategic focus on Enact as a cash engine and CareScout as a growth platform, while maintaining the self-sustainability of the Closed Block through ongoing rate actions.

Base Case: Steady De-risking and Platform Validation

In the base case, the U.S. housing market remains stable with modest growth, and CareScout successfully achieves its moderate revenue targets. The Closed Block continues to benefit from MYRAP, keeping statutory capital levels stable.

  • Financial Drivers: Enact NIW grows at a 2% CAGR as the housing market recovers from high rates.[12] CareScout revenue reaches $100 million ARR by 2030, achieving break-even profitability by 2028.[2]
  • Share Repurchases: The company continues to repurchase $200 million of stock annually, reducing the share count to approximately 275 million by 2031.[11]
  • Valuation Assumption: The market begins to partially lift the "LTC discount," re-rating the stock to 0.5x P/B.
  • LTC Performance: A/E experience remains within 5% of expectations; no additional capital is required for GLIC.[10]
  • Projected Share Price (2031): $15.80.

High Case: CareScout Breakout and Legal Windfall

The high case assumes a major breakout for the CareScout platform, potentially including partnerships with other major insurers, and a successful conclusion to the AXA litigation.

  • Financial Drivers: CareScout revenue reaches $250 million ARR by 2030, with 30% operating margins.[2] Genworth receives a $750 million net recovery from AXA in 2027, which is used to accelerate buybacks or retire all remaining holding company debt.[11]
  • Share Repurchases: Aggressive buybacks reduce the share count to 210 million by 2031.[11]
  • Valuation Assumption: The company is viewed as a "healthcare technology" hybrid rather than a legacy insurer, commanding a 12x P/E on normalized earnings.
  • LTC Performance: Favorable mortality trends and higher interest rates lead to a statutory capital surplus, allowing for a potential (though unlikely) resumption of dividends from legacy units by 2031.[10]
  • Projected Share Price (2031): $32.50.

Low Case: Economic Recession and Reserve Failure

The low case assumes a severe economic downturn that impacts home prices and employment, combined with a significant reserve deficiency in the LTC block.

  • Financial Drivers: Enact loss ratios spike to 60%, and capital returns to the holding company are suspended by regulators to preserve PMIERs.[21] CareScout growth stalls at $40 million revenue, remaining a cash drag on the parent company.[5]
  • Share Repurchases: The buyback program is suspended in 2027 to preserve liquidity.
  • Valuation Assumption: The stock remains a "value trap," trading at 0.15x P/B.
  • LTC Performance: Unfavorable claim experience necessitates a $2 billion reserve strengthening in 2028, forcing a dilutive capital raise or regulatory conservatorship of the legacy insurance entities.[10]
  • Projected Share Price (2031): $1.45.

Share Price Trajectory Table

Year Base Case (USD) High Case (USD) Low Case (USD)
2026 (Current) $7.99 $7.99 $7.99
2027 $9.20 $12.50 $6.10
2028 $10.80 $17.20 $4.50
2029 $12.50 $22.00 $3.20
2030 $14.10 $27.00 $2.10
2031 (Target) $15.80 $32.50 $1.45

[1, 2, 5, 11, 18]

Probability Weighted Outcome

Scenario Subjective Probability Weighted Price Target (USD)
Base Case 60% $9.48
High Case 25% $8.13
Low Case 15% $0.22
Blended Target 100% $17.83

NAVIGATING TAIL RISKS

6. Qualitative Scorecard:

Each metric is scored on a scale of 1–10, where 10 represents industry-leading performance.

  • Management Alignment: 9/10
    Management incentives are strongly tied to free cash flow and relative Total Shareholder Return (TSR).[25] The CEO's 6x salary stock ownership requirement and the aggressive $790 million share repurchase program since 2022 demonstrate a clear commitment to shareholder value.[11, 25] Insider sales in early 2026 appear related to tax withholding on RSU vestings rather than a change in conviction.[26, 27]
  • Revenue Quality: 6/10
    Genworth possesses a "Jekyll and Hyde" revenue profile. Enact’s premium revenue is high-margin and persistent, but it is currently offset by the negative margins and actuarial volatility of the Closed Block.[8, 12] CareScout’s fee-based revenue is high-potential but currently too small to impact the consolidated profile significantly.[2, 5]
  • Market Position: 7/10
    Enact maintains a steady 17% market share in the competitive U.S. mortgage insurance space, standing as a top-tier provider alongside MGIC and Radian.[28] Genworth’s early move into the integrated senior care platform space gives it a potential "first-mover" advantage if CareScout can achieve scale.[2]
  • Growth Outlook: 8/10
    While the legacy block is in runoff, the growth opportunity in the aging-care market is profound.[9] The 71 million Americans aging into the "care bracket" by 2029 provide a massive tailwind for CareScout's provider-matching and care-planning services.[9]
  • Financial Health: 7/10
    The company is in its best financial position since 2014, with $234 million in holding company cash and a consolidated RBC ratio of 300% for its legacy units.[8, 11] However, the $55 billion in future policy benefits remains a massive long-term liability that constrains the credit profile.[19]
  • Business Viability: 6/10
    The Enact and CareScout businesses are highly durable. The central "choke point" is the legacy LTC block; if those entities become insolvent and regulators attempt to reach into the parent company’s other assets, the entire corporate structure would be threatened.[5, 10]
  • Capital Allocation: 9/10
    Management has been exceptionally disciplined, prioritizing holding company debt reduction and then returning virtually all excess cash to shareholders via buybacks.[1, 5] They have avoided the "growth at any cost" acquisitions common in the sector, opting instead for strategic, low-cost "tuck-ins" like Seniorly.[1, 9]
  • Analyst Sentiment: 6/10
    The consensus rating is "Moderate Buy" with a target of $10.00.[29, 30] Most analysts acknowledge the deep value in the Enact stake but remain hesitant to recommend a higher valuation until the Closed Block shows multi-quarter stability.[5]
  • Profitability: 5/10
    Adjusted operating income of $144 million on $7.3 billion in revenue represents a thin margin, reflecting the drag from legacy losses.[3, 8] Operating leverage will only improve if CareScout scales and legacy losses continue to moderate through MYRAP.[2, 5]
  • Track Record: 4/10
    The long-term history of Genworth is defined by significant shareholder value destruction due to the legacy of long-term care insurance.[31, 32] Current management has done an admirable job of "fixing" the company since 2021, but it will take years of consistent performance to erase the memory of past volatility.[5, 31]

OVERALL BLENDED SCORE: 6.7/10

COMPLEX TURNAROUND STORY

7. Conclusion & Investment Thesis:

Genworth Financial Inc (GNW) represents a compelling "sum-of-the-parts" opportunity where the current market price significantly undervalues the company’s underlying assets.[5] The investment thesis is centered on the successful execution of the "two-pillar" strategy: leveraging the robust cash flows from Enact to build a dominant, capital-light platform in the senior care market through CareScout.[2, 5]

The Case for Undervaluation

The fundamental disconnect in the GNW story is the valuation of its Enact stake.[4, 20] At current market prices, Genworth's ~81% interest in Enact is worth roughly $1.7 billion more than Genworth’s entire consolidated market capitalization.[4, 5] This implies that the market is assigning a negative value to Genworth’s $234 million in cash, its multi-billion dollar investment portfolio, and the long-term growth potential of CareScout.[5, 11] As management continues to retire shares—having already reduced the share count by 24%—the per-share claim on Enact’s value will continue to rise.[11]

Strategic Catalysts

  • CareScout Revenue Breakout: Achieving the 2026 revenue target of $25 million would validate the shift toward fee-based services and potentially lead to a re-rating of the company’s multiple.[5]
  • AXA Litigation Windfall: A $750 million recovery would provide a significant liquidity buffer to accelerate the "closed system" strategy for the legacy block.[11]
  • Housing Market Resilience: Continued high persistency and low loss ratios in the mortgage insurance segment will ensure a steady stream of upstreamed dividends to the parent company.[7, 15]

Residual Risks

The primary risk remains the "tail risk" of the legacy LTC block.[5, 10] While management has built a firewall by managing these companies as a self-sustaining system, any catastrophic actuarial failure could still have ripple effects across the enterprise.[2, 10] Furthermore, the company’s pivot to healthcare services via CareScout is still in its early stages and faces execution risk as it attempts to sign up third-party carriers.[2, 5]

Overall, Genworth Financial is a company that has moved past its "crisis phase" and is now in its "transformation phase." For investors, the stock remains a play on management’s ability to extract value from Enact while navigating the long-dated liabilities of the past.

TRANSFORMATION THROUGH EXECUTION

8. Technical Analysis, Price Action & Short-Term Outlook:

Genworth’s current stock price of $7.99 is trading below its 200-day moving average of $8.517, suggesting a technical downtrend and immediate resistance at that level.[26, 33] The price action has been volatile following the fourth-quarter 2025 earnings miss, though it has found recent support in the $7.85-$8.00 range.[18, 34] In the short term, the stock is likely to remain range-bound between $7.80 and $8.50 as investors digest the implications of the Seniorly acquisition and wait for the first quarter 2026 results to confirm the revenue trajectory of CareScout.[1, 5]

TECHNICAL SUPPORT TEST


  1. GNW SEC Filings - Genworth Finl Inc 10-K, 10-Q, 8-K Forms, https://www.stocktitan.net/sec-filings/GNW/page-2.html
  2. What is Growth Strategy and Future Prospects of Genworth Financial Company?, https://portersfiveforce.com/blogs/growth-strategy/genworth
  3. Genworth Financial, Inc. (GNW), https://investor.genworth.com/
  4. ACT SEC Filings - Enact Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/ACT/page-6.html
  5. Genworth targets $25M CareScout revenue in 2026 as company accelerates platform expansion - Seeking Alpha, https://seekingalpha.com/news/4556034-genworth-targets-25m-carescout-revenue-in-2026-as-company-accelerates-platform-expansion
  6. Enact Holdings (ACT) posts 2025 net income of $674M and strong capital - Stock Titan, https://www.stocktitan.net/sec-filings/ACT/10-k-enact-holdings-inc-files-annual-report-ed4107fec707.html
  7. Enact Holdings, Inc. SEC 10-K Report - TradingView, https://www.tradingview.com/news/tradingview:1800db2823d71:0-enact-holdings-inc-sec-10-k-report/
  8. Genworth Financial Announces Fourth Quarter 2025 Results, https://investor.genworth.com/news-events/press-releases/detail/1053/genworth-financial-announces-fourth-quarter-2025-results
  9. Genworth Q4 2025 slides: earnings miss estimates as CareScout expands - Investing.com, https://www.investing.com/news/company-news/genworth-q4-2025-slides-earnings-miss-estimates-as-carescout-expands-93CH-4521910
  10. Genworth Financial, Inc. (GNW) Q4 2025 Earnings Call Transcript ..., https://seekingalpha.com/article/4873941-genworth-financial-inc-gnw-q4-2025-earnings-call-transcript
  11. GNW Q4-2025 Earnings Call - Alpha Spread, https://www.alphaspread.com/security/nyse/gnw/investor-relations/earnings-call/q4-2025
  12. 8-K - 02/23/2026 - Genworth Financial, Inc., https://investor.genworth.com/sec-filings/all-sec-filings/content/0001628280-26-010610/0001628280-26-010610.pdf
  13. Genworth Financial, Inc., https://investor.genworth.com/sec-filings/all-sec-filings/content/0001628280-26-012828/0001628280-26-012828.pdf
  14. U.S. Private Mortgage Insurance Sector View 2026: Strength Amid Rising Challenges, https://www.spglobal.com/ratings/en/regulatory/article/us-private-mortgage-insurance-sector-view-2026-strength-amid-rising-challenges-s101661481
  15. Genworth Investor Presentation - Cloudfront.net, https://d1io3yog0oux5.cloudfront.net/_bf953926e846d6deb0021ffbfd745974/genworth/db/2265/23038/pdf/2Q25+Earnings+Presentation+-+FINAL.pdf
  16. U.S. mortgage insurance sector on solid footing in 2026: Fitch - Scotsman Guide, https://www.scotsmanguide.com/news/us-mortgage-insurance-sector-on-solid-footing-in-2026/
  17. CareScout Releases 2025 Cost of Care Data for New Hampshire - Business Wire, https://www.businesswire.com/news/home/20260302143064/en/CareScout-Releases-2025-Cost-of-Care-Data-for-New-Hampshire
  18. GNW Stock Price Quote & News - Genworth Financial - Robinhood, https://robinhood.com/us/en/stocks/GNW/
  19. Balance Sheet - Genworth Financial, Inc., https://investor.genworth.com/financial-information/balance-sheet
  20. Enact Holdings Inc Compare against Competitors - Investing.com, https://www.investing.com/pro/NASDAQGS:ACT/compare/NASDAQGM:NMIH,NYSE:RDN,NYSE:ESNT,NYSE:MTG,NASDAQGS:ACGL,NASDAQGS:CINF
  21. Research Update: Enact Holdings Inc. Outlook Revi | S&P Global Ratings, https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3503728
  22. CareScout Releases 2025 Cost of Care Survey Results - Business Wire, https://www.businesswire.com/news/home/20260302283881/en/CareScout-Releases-2025-Cost-of-Care-Survey-Results
  23. CareScout Survey Shows Long-Term Care Cost Growth Slows in 2025 - Sahm, https://www.sahmcapital.com/news/content/carescout-survey-shows-long-term-care-cost-growth-slows-in-2025-2026-03-02
  24. CareScout Releases 2025 Cost of Care Survey Results - Genworth Financial, Inc., https://investor.genworth.com/news-events/press-releases/detail/1054/carescout-releases-2025-cost-of-care-survey-results
  25. 8-K - 03/19/2025 - Genworth Financial, Inc., https://investor.genworth.com/sec-filings/all-sec-filings/content/0001193125-25-057867/0001193125-25-057867.pdf
  26. Genworth Financial, Inc. (GNW) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/GNW
  27. GNW SEC Filings - Genworth Finl Inc 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/GNW/page-3.html
  28. ESNT: August 2025 Investor Presentation, https://s1.q4cdn.com/417295621/files/doc_presentations/2025/Aug/11/ESNT-Investor-Presentation-August-2025.pdf
  29. Genworth Financial Stock Forecast & Predictions: 1Y Price Target $10.00 | Buy or Sell NYSE: GNW 2026 | WallStreetZen, https://www.wallstreetzen.com/stocks/us/nyse/gnw/stock-forecast
  30. Genworth Financial (GNW) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NYSE/GNW/forecast/
  31. Genworth Company Stability & Growth 2026 | Built In, https://builtin.com/company/genworth/faq/stability-growth
  32. EX-99.1 - Genworth Financial, https://investor.genworth.com/sec-filings/all-sec-filings/content/0001193125-14-035097/d645069dex991.htm
  33. Genworth Stock Technical Analysis (GNW) - Investing.com Canada, https://ca.investing.com/equities/genworth-finl-technical
  34. Historical Data - Genworth Financial, Inc., https://investor.genworth.com/stock-data/historical-data

View Genworth Financial, Inc. (GNW) stock page

Loading the interactive version of this report…